Lilly, Astellas Circle Sangamo Assets as Biotech Files for Bankruptcy

Why It Matters

The transactions give Lilly and Astellas early access to cutting‑edge gene‑therapy platforms at distressed prices, accelerating their pipelines and reshaping the biotech M&A landscape.

Key Takeaways

• Lilly and Astellas act as stalking‑horse bidders in Sangamo’s Chapter 11 auction
• $18 million upfront paid to Sangamo for AAV capsid technology
• Astellas targets Fabry disease therapy ST‑920 for acquisition
• Sangamo retains 77 staff to support assets under sale

Pulse Analysis

Sangamo Therapeutics’ Chapter 11 filing underscores the growing financial strain on mid‑stage biotech firms that rely heavily on capital‑intensive gene‑therapy programs. While the company’s cash runway expired in early 2025, its portfolio of proprietary delivery platforms and rare‑disease candidates retained strategic value. The bankruptcy process allows Sangamo to reorganize under court supervision, preserving core talent and enabling a structured asset sale that could maximize recovery for creditors and shareholders.

Eli Lilly’s bid centers on Sangamo’s adeno‑associated virus capsid (STAC‑BBB), zinc‑finger nucleases, and modular integrase systems—technologies that promise more efficient central‑nervous‑system targeting and broader genome‑editing applications. The $18 million upfront fee, part of a larger potential $1.4 billion deal, reflects Lilly’s willingness to lock in a platform that could accelerate its own CNS pipeline and reduce reliance on external licensing. Astellas, meanwhile, is eyeing the Fabry disease gene therapy isaralgagene civaparvovec, a pivotal‑stage candidate with promising renal outcomes, positioning the Japanese pharma giant to expand its rare‑disease franchise.

For investors and industry observers, the Sangamo sale illustrates how distressed assets can become catalysts for larger players to acquire high‑value technology at a discount. The inclusion of deal protections for the stalking‑horse bidders may set a precedent for future bankruptcy‑driven transactions in the biotech sector. As the assets transition to new owners, the accelerated development of therapies for Fabry disease, prion disorders, and hemophilia A could reshape competitive dynamics and bring novel treatments to market faster than organic R&D alone would allow.

Deal Summary

Sangamo Therapeutics, which filed for Chapter 11 bankruptcy, signed asset‑sale agreements with Eli Lilly and Astellas Pharma, making them stalking‑horse bidders for Sangamo’s gene‑therapy platforms. The deals transfer Sangamo’s capsid delivery, zinc‑finger, modular integrase platforms and a prion‑disease program to Lilly, and a Fabry disease gene therapy to Astellas. Financial terms were not disclosed, though Lilly previously paid $18 million upfront for a licensing arrangement.